Immature platelet fraction over time and clinical outcomes in patients with acute myocardial infarction

Yahud, Ella; Schilo, Tamar; Nevzorov, R.; Asher, Elad; Bryk, Gabriel; Laish-Farkash, Avishag; Lev, Eli I.

doi:10.1111/ijlh.13499

Cited by 6 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these results, the opportunity to defer platelet transfusions that would be given when transfusion decisions are based on platelet counts only 21 . IP has also been implicated in several pathologies, such as acute myocardial injury and sepsis, and has been found to be an early predictor of worsening in severe COVID‐19 patients 22–24 . The use of IP measurement, particularly with citrated anticoagulant, could help in patients with pseudothrombocytopenia induced by EDTA anticoagulant.…”

Section: Discussionmentioning

confidence: 99%

“…21 IP has also been implicated in several pathologies, such as acute myocardial injury and sepsis, and has been found to be an early predictor of worsening in severe COVID-19 patients. [22][23][24] The use of IP measurement, particularly with citrated anticoagulant, could help in patients with pseudothrombocytopenia induced by EDTA anticoagulant. This study has limitations, including the use of only one hematological analyzer and the lack of checking of platelet counts obtained with the reference.…”

Section: Evaluation Between 1 and 24 H In Edta Sample For Ipf (A) And...mentioning

confidence: 99%

See 1 more Smart Citation

Stability over time of immature platelet fraction and comparison between EDTA and citrated whole blood samples

Noel

Feugray

Kasonga

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundImmature platelets (IP) are the youngest circulating platelets, released from megakaryocytes, and demonstrating increased dimensions, significant RNA content, and enhanced activity. Immature platelet research focuses on a differential diagnostic help in patients with thrombocytopenia. The objectives of this study were to compare the variability of IP in citrate and EDTA samples, and to determine stability over time.MethodsFifty‐six patients were included for comparison between EDTA and citrate whole blood sample collection. Among the patients, 28 had thrombocytopenia (platelet count < 150G/L). Platelet measurement impedancemetry and fluorimetry were performed with Sysmex XN‐9000. The immature platelet fraction (IPF) and absolute immature platelet count (A‐IPC) were determined with a fluorescent method.ResultsThe mean value of platelet count with fluorescence was, in EDTA sample, 215 ± 171 and, in citrate sample, 153 ± 118 G/L. No significant difference was observed between IPF between EDTA and citrate (7.74 ± 6.68% vs. 8.45 ± 7.37%, p = 0.69), respectively. With the Bland–Altman analysis, the mean difference in the EDTA sample, between 1 and 24 h, was 8.06 ± 6.96% and 8.73 ± 7.12% for IPF, whereas in the citrate sample, between 1 and 6 h, it was 8.60 ± 7.29% and 7.54 ± 6.97%, for IPF. Comparing 1 h EDTA sample with 6 h citrate sample, the variance ratio was 0.974 (95% CI: 0.864–1.084) in IPF.ConclusionsWe confirmed the potential to conduct IP measurements up to 24 h in the EDTA sample and IPF measurements in the citrate sample for up to 6 h. These results may be useful for the use of IPF, which is a promising parameter whose interest in clinical practice and standardization is not yet well defined.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Evaluation Between 1 and 24 H In Edta Sample For Ipf (A) And...mentioning

confidence: 99%

Stability over time of immature platelet fraction and comparison between EDTA and citrated whole blood samples

Noel

Feugray

Kasonga

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Thus, they are suspected to be implicated in thrombosis during some pathological settings. Indeed, higher troponin levels were associated with higher IP fractions during acute myocardial injury, with a subsequent association with worse cardiac outcomes [ 24 ]. During sepsis, higher A-IPC seems to be associated with the severity and prognosis of patients [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Routine and Advanced Laboratory Tests for Hemostasis Disorders in COVID-19 Patients: A Prospective Cohort Study

Billoir

Leprêtre

Thill

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Thrombosis is frequent during COVID-19 disease, and thus, identifying predictive factors of hemostasis associated with a poor prognosis is of interest. The objective was to explore coagulation disorders as early predictors of worsening critical conditions in the intensive care unit (ICU) using routine and more advanced explorations. Materials: Blood samples within 24 h of ICU admission for viscoelastic point-of-care testing, (VET), advanced laboratory tests: absolute immature platelet count (A-IPC), von Willebrand-GPIb activity (vWF-GpIb), prothrombin fragments 1 + 2 (F1 + 2), and the thrombin generation assay (TGA) were used. An association with worse outcomes was explored using univariable and multivariable analyses. Worsening was defined as death or the need for organ support. Results: An amount of 85 patients with 33 in critical condition were included. A-IPC were lower in worsening patients (9.6 [6.4–12.5] vs. 12.3 [8.3–20.7], p = 0.02) while fibrinogen (6.9 [6.1–7.7] vs. 6.2 [5.4–6.9], p = 0.03), vWF-GpIb (286 [265–389] vs. 268 [216–326], p = 0.03) and F1 + 2 (226 [151–578] vs. 155 [129–248], p = 0.01) were higher. There was no difference observed for D-dimer, TGA or VET. SAPS-II and A-IPC were independently associated with worsening (OR = 1.11 [1.06–1.17] and OR = 0.47 [0.25–0.76] respectively). The association of a SAPS-II ≥ 33 and an A-IPC ≤ 12.6 G/L predicted the worsening of patients (sensitivity 58%, specificity 89%). Conclusions: Immature platelets are early predictors of worsening in severe COVID-19 patients, suggesting a key role of thrombopoiesis in the adaption of an organism to SARS-CoV-2 infection.

show abstract

“…Recent studies have demonstrated an association between high immature platelet fraction (IPF) and increased thrombotic events in patients with ACS [11–14]. Higher levels of IPF have been identified as predictors of 1-year cardiac mortality in patients with AMI [12–14]. In a recent study conducted by our group, elevated IPF levels in the first month following AMI were linked to unfavorable clinical outcomes at 1 year [13].…”

Section: Introductionmentioning

confidence: 99%

“…Higher levels of IPF have been identified as predictors of 1-year cardiac mortality in patients with AMI [12–14]. In a recent study conducted by our group, elevated IPF levels in the first month following AMI were linked to unfavorable clinical outcomes at 1 year [13].…”

Section: Introductionmentioning

confidence: 99%

Correlation between baseline immature platelets fraction levels and peak troponin in patients with acute myocardial infarction

Roguin,

Dahan,

Reiner-Benaim

et al. 2023

Coronary Artery Disease

Self Cite

View full text Add to dashboard Cite

Introduction Elevated peak cardiac troponin levels have been linked with increased morbidity and mortality in patients with acute myocardial infarction (AMI). Immature Platelets are young and relatively large platelets that are hyper-reactive and pro-thrombotic compared to regular platelets. Increased immature platelet fraction (IPF) has been associated with an elevated risk of thrombotic events. We hypothesize that patients with higher IPF levels during AMI, will experience a more severe infarct, leading to elevated peak troponin levels. Methods Clinical data from patients admitted to the cardiology division between 2018 and 2022, who were diagnosed with AMI and underwent an IPF testing. Univariate and multivariate regression analyses were performed to identify predictors of elevated peak troponin. Results Among the 277 patients diagnosed with AMI who underwent IPF testing, 113 had (STEMI) and 164 had (NSTEMI). The median value of IPF of 4.2% was used as the threshold for defining elevated IPF. Notably, among STEMI patients, those with IPF ≥ 4.2% had significantly higher peak troponin levels (P = 0.021). Conversely, no significant difference in peak troponin levels was observed among NSTEMI patients (P = 0.348). Multivariate analysis identified patients with STEMI in the higher IPF group as one of the significant predictors for elevated peak troponin levels. Conclusion This study revealed a correlation between higher baseline IPF levels and increased peak troponin levels specifically in STEMI patients, while no such association was found in NSTEMI patients. Incorporating IPF levels above the median into risk stratification scores for STEMI patients may provide valuable support for adopting a more proactive therapeutic approach.

show abstract

Immature platelet fraction over time and clinical outcomes in patients with acute myocardial infarction

Cited by 6 publications

References 26 publications

Stability over time of immature platelet fraction and comparison between EDTA and citrated whole blood samples

Stability over time of immature platelet fraction and comparison between EDTA and citrated whole blood samples

Routine and Advanced Laboratory Tests for Hemostasis Disorders in COVID-19 Patients: A Prospective Cohort Study

Correlation between baseline immature platelets fraction levels and peak troponin in patients with acute myocardial infarction

Contact Info

Product

Resources

About